In the BioHarmony Drug Report Database
Ropivacaine
Naropin, Exparel (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It has been approved in Europe to treat acute pain. It is known to target sodium channel protein type 5 subunit alpha. Naropin’s patent is valid until 2026-11-28 (FDA).
Trade Name
|
Exparel liposomal |
|---|---|
Common Name
|
ropivacaine |
ChEMBL ID
|
CHEMBL1077896 |
Indication
|
acute pain, postoperative pain |
Drug Class
|
Local anesthetics |
Image (chem structure or protein)